Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

The following documentation and opinions were made available to the Committee:

A. The assessment report for this appraisal was prepared by The University of Sheffield, School of Health and Related Research:

I) Ward S, Kaltenthaler E, Cowan J, et al. A Review of the Evidence for the Clinical and Cost Effectiveness of Capecitabine and Tegafur with Uracil for the Treatment of Metastatic Colorectal Cancer, 23 September 2002

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the appraisal consultation document. Consultee organisations were provided with the opportunity to appeal against the FAD:

I) Manufacturer/sponsors:

  • Bristol-Myers Squibb

  • Roche Products Limited

II) Professional/specialist and patient/carer groups:

  • Association of Coloproctology of Great Britain and Ireland

  • Association of Surgeons of Great Britain and Ireland

  • Beating Bowel Cancer

  • British Geriatrics Society

  • British Psychosocial Oncology Society

  • British Oncology Pharmacy Association

  • CancerBACUP

  • Colon Cancer Concern

  • Department of Health

  • Macmillan Cancer Relief

  • National Cancer Alliance

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Physicians

  • Royal College of Radiologists

  • Royal Pharmaceutical Society of Great Britain

  • Welsh Assembly Government

  • Welsh Cancer Network

III) Commentator organisations (without the right of appeal):

  • Croydon Primary Care Trust

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Cancer Steering Group

  • NHS Quality Improvement Scotland

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on capecitabine and tegafur with uracil for metastatic colorectal cancer by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD:

  • Professor David Cunningham, Consultant Medical Oncologist, Specialist in Gastrointestinal Cancer and Lymphoma, The Royal Marsden Hospital

  • Dr Matthew Seymour, Senior Lecturer & Honorary Consultant, ICRF Cancer Medicine Research Centre

  • Dr Chris Twelves, Beaston Oncology Centre, Western Infirmary, University of Glasgow

  • Jola Gore-Booth, Chief Executive, Colon Cancer Concern

  • Lynne Jones, Resources Librarian, Colon Cancer Concern